4-Bromo-3-nitrotoluene | CAS:5326-34-1

We serve 4-Bromo-3-nitrotoluene CAS:5326-34-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-3-nitrotoluene

Chemical Name:4-Bromo-3-nitrotoluene
CAS.NO:5326-34-1
Synonyms:4-Bromo-3-nitrotoluene
1-Bromo-4-methyl-2-nitrobenzene
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 252.2±20.0 °C at 760 mmHg
Melting Point 31-33 °C(lit.)
Molecular Formula C7H6BrNO2
Molecular Weight 216.032
Flash Point 106.3±21.8 °C
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.593
 
Specification:
Appearance:Yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Bromo-3-nitrotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Bromo-4-methyl-2-nitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-4-methyl-2-nitrobenzene Use and application,4-Bromo-3-nitrotoluene technical grade,usp/ep/jp grade.


Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.4-(Trifluoromethoxy)benzenesulfonamide manufacturer “Our priority is not only to protect and inform the residents of Boston but also to help this man continue to recover.1-Bromopyrene supplier “Our priority is not only to protect and inform the residents of Boston but also to help this man continue to recover.N-Methyl-N-Cbz-D-alanine vendor Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.